NAION & Ozempic Lawsuit – Vision Loss Claims & Free Case Review
If you took Ozempic, Wegovy, or another GLP-1 drug and were diagnosed with NAION (sudden vision loss), you may qualify for a free case review. Lawsuits allege manufacturers failed to warn about the risk of Non-Arteritic Anterior Ischemic Optic Neuropathy. Confidential, no obligation.
Top Tier Legal LLC is not a law firm and does not provide legal advice. Submitting does not create an attorney-client relationship. If we share your information with a law firm, it is for evaluation only; the firm will independently decide whether to contact you. Outcomes are not guaranteed.
You may qualify if:
- You took Ozempic, Wegovy, Saxenda, Mounjaro, Zepbound, or another GLP-1 (semaglutide / tirzepatide) drug
- You were diagnosed with NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) or sudden vision loss
- Vision loss or NAION occurred after starting the medication
- Statutes of limitations vary by state—contact us soon
You can submit even if you don't have all records yet.
NAION & Ozempic Lawsuit News & Updates HubWho May Qualify
You may be eligible for a free NAION / Ozempic legal case review if you took a GLP-1 medication (such as Ozempic, Wegovy, Saxenda, Mounjaro, or Zepbound) and were later diagnosed with NAION—Non-Arteritic Anterior Ischemic Optic Neuropathy—or experienced sudden, painless vision loss. The following factors may indicate eligibility:
- Used Ozempic, Wegovy, Saxenda, Mounjaro, Zepbound, or another semaglutide or tirzepatide product
- Diagnosed with NAION or sudden vision loss (optic nerve damage)
- Vision loss or NAION occurred after starting the medication
- Prescribed for type 2 diabetes or weight loss
If you believe you may qualify, we encourage you to submit your information for a free case review. Our review process helps determine if you may be connected with an independent law firm for evaluation of a potential claim.
What is NAION?
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is sudden, painless, and typically permanent vision loss caused by disrupted blood flow to the optic nerve. It affects roughly 21,000 Americans each year and currently has no effective treatment. Vision loss may occur in one or both eyes.
Lawsuits allege that GLP-1 drugs such as Ozempic (semaglutide) and Mounjaro (tirzepatide) may increase the risk of NAION and that manufacturers failed to adequately warn patients and doctors.
The Link Between GLP-1 Drugs and NAION
A July 2024 study published in JAMA Ophthalmology (Harvard-affiliated researchers) found that users of semaglutide had a significantly elevated risk of NAION: about 4.28 times higher for people with type 2 diabetes and about 7.64 times higher for those using the drug for weight loss, compared to non-users.
In June 2025, the European Medicines Agency (EMA) added NAION as a "very rare" side effect for semaglutide-containing medicines. The FDA had not added a NAION warning to U.S. labels as of early 2026—a gap that is central to plaintiffs' failure-to-warn claims.
Which Drugs Are Involved?
Ozempic / Wegovy
Semaglutide (Novo Nordisk)—type 2 diabetes and weight loss
Saxenda
Liraglutide (Novo Nordisk)—weight loss
Mounjaro / Zepbound
Tirzepatide (Eli Lilly)—type 2 diabetes and weight loss
Trulicity
Dulaglutide (Eli Lilly)—type 2 diabetes
Get the full picture: MDL status, key dates, science & FAQ
NAION & Ozempic Lawsuit News & Updates HubNAION / Ozempic MDL & Litigation Updates
Federal lawsuits alleging that Ozempic and other GLP-1 drugs caused NAION (vision loss) are consolidated in MDL No. 3163, In re: GLP-1 RA Products Liability Litigation (No. II), in the Eastern District of Pennsylvania under Judge Karen S. Marston. The MDL was created in December 2025. Plaintiffs allege that Novo Nordisk and Eli Lilly failed to warn about the risk of NAION. Additional cases are pending in state court, including in New Jersey.
Current Status
- Federal NAION/GLP-1 cases centralized in MDL 3163 (E.D. Pa.)
- Litigation is in early stages; discovery and bellwether planning ongoing
- EMA added NAION as very rare side effect (June 2025); FDA label update pending
- Statutes of limitations vary by state—contact us for a free case review
Time limits may apply. Submit your information for a free, confidential case review to see if you may qualify to be connected with a law firm handling these claims.
Projected NAION / Ozempic Settlement Amounts
No settlements have been reached yet. Based on similar drug injury and vision-loss cases, lawyers and analysts estimate potential compensation ranges by severity. Outcomes depend on litigation developments and your individual facts.
| Severity | Description | Estimated Range |
|---|---|---|
| High Severity | Bilateral NAION, severe permanent vision loss or legal blindness | $1,500,000 – $3,000,000+ |
| Moderate–High | Unilateral NAION with significant permanent vision loss | $300,000 – $800,000 |
| Moderate | Unilateral NAION with partial vision loss, impact on daily life | $150,000 – $400,000 |
These are estimates only. No guarantee of recovery. Law firms typically work on contingency—you generally pay only if there is a recovery.
Evidence Linking GLP-1 Drugs to NAION
Peer-reviewed research has raised concerns about an association between GLP-1 receptor agonists (e.g., semaglutide) and NAION. Plaintiffs allege that manufacturers knew or should have known of this risk and failed to warn.
JAMA Ophthalmology (July 2024)
A study of 16,827 patients found that semaglutide users had a significantly higher cumulative incidence of NAION (8.9%) compared to non-users (1.8%). For people with type 2 diabetes, the risk was about 4.28 times higher; for those using semaglutide for weight loss, the risk was about 7.64 times higher.
Key finding: 4.28x–7.64x increased NAION risk with semaglutide
European Medicines Agency (June 2025)
The EMA added NAION as a "very rare" side effect to the product information for semaglutide-containing medicines (e.g., Ozempic, Wegovy). This regulatory action supports allegations that the risk was known or knowable and that U.S. labeling should have been updated.
Key finding: EMA recognizes NAION as very rare adverse effect
NAION / Ozempic Litigation & Legal Resources
If you took Ozempic, Wegovy, or another GLP-1 drug and were diagnosed with NAION or sudden vision loss, a free case review can help you understand your options and whether you may be connected with a law firm handling these claims.
Latest MDL status, key dates, and legal developments.
Overview of dangerous drug claims and how we connect you with law firms.
Legal disclaimer
Top Tier Legal LLC is not a law firm and does not provide legal advice. Submitting does not create an attorney-client relationship. If we share your information with a law firm, it is for evaluation only; the firm will independently decide whether to contact you. Outcomes are not guaranteed.
Start Your Free NAION / Ozempic Case Review
Time limits may apply. If you took Ozempic or another GLP-1 drug and were diagnosed with NAION or sudden vision loss, contact us today for a free, confidential case review to see if you may qualify and be connected with a law firm handling these claims.